Subscribe To
Why is novocure (nvcr) stock down 30% today?
Shares of innovative biotechnology firm Novocure (NASDAQ: NVCR ) cratered badly, losing 30% on Monday morning before fading even further in the early ...
August 28, 2023, 2:53 pm
String of q2 earnings beat fails to lift retail etfs
Total earnings from 96.3% of the sector's total market capitalization reported so far are up 23.9% on 5.5% higher revenues, with 78.6% beating EPS est...
August 28, 2023, 12:47 pm
Canadian autoworkers at ford, gm and stellantis overwhelmingly approve strike mandate
Canadian automakers have joined their U.S. counterparts in authorizing strike action should union negotiators ...
August 28, 2023, 12:11 pm
Novocure stock plummets after phase 3 cancer trial fails to reach desired endpoint
Novocure (NASDAQ:NVCR) shares are down nearly a third Monday after a Phase 3 study of its Tumor Treating Fields therapy was reported to have ...
August 28, 2023, 12:04 pm
Merck (mrk), eisai to end keytruda-lenvima combo cancer study
With the phase III LEAP-010 study failing to show an overall survival benefit for patients with recurre...
August 28, 2023, 12:02 pm
Exxon projects oil, gas to be 54% of world's energy needs in 2050
Oil and natural gas are still projected to meet more than half of the world's energy needs in 2050, or 54%, Exxon Mobil Corp. said on Monday, with the...
August 28, 2023, 11:56 am
Arm ipos on nvidia's success and ai hype. here's why i'm not touching it
Nvidia wanted to acquire the company for $40 billion and failed. Arm is reported to be valued at $60 bi...
August 28, 2023, 10:50 am
3m agrees to $5.5b settlement in defective earplugs lawsuits
3M Co (NYSE:MMM) has tentatively agreed to pay more than $5.5 billion to resolve over 300,000 lawsuits alleging that the company sold defective combat...
August 28, 2023, 9:47 am
Novocure shares plunge after ovarian cancer study failure
Shares of Novocure Ltd. NVCR, -0.77% dropped 37% premarket on Monday after the Swiss oncology company said a late-stage trial of Tumor Treating Fields...
August 28, 2023, 8:34 am
Diamondback energy: growth story
Diamondback Energy emphasizes per share growth as part of return to shareholders, with a focus on rapid cash flow growth. Management has a history of ...
August 28, 2023, 7:40 am
Novocure's cancer therapy fails to meet main goal in late-stage trial
Novocure said on Monday its therapy failed in a late-stage trial to meet the main goal of improving sur...
August 28, 2023, 7:35 am
Intraday analysis – usd keeps its edge
EURUSD still under pressure The US dollar advanced after Jerome Powell stated that the Fed’s tightening campaign was not over. On the daily chart, t...
August 28, 2023, 6:18 am
3m likely to settle for nearly $5.5b in earplugs case after hearing-loss complaints
3M is nearing a multibillion-dollar settlement with plaintiffs to resolve complaints by veterans that the company's earplugs ...
August 28, 2023, 6:05 am
Focus: tesla braces for its first trial involving autopilot fatality
Tesla Inc is set to defend itself for the first time at trial against allegations that failure of its A...
August 28, 2023, 6:05 am
Dublin tech ceo sentenced to two years in prison for ppp loan scheme
A Dublin man who works as CEO of four tech and IT companies in the Bay Area was sentenced to two years in prison for conspiracy to commit bank fraud a...
August 28, 2023, 12:00 am
Gold fails to shine as prices for the safe-haven asset slip despite fitch ratings’ downgrade
Gold prices are up around 4.7% on the MCX year-to-date. Gold prices saw a tailwind as global rating agency Fitch Ratings downgraded the US government�...
August 25, 2023, 11:59 pm
York county fails to qualify for low-interest loans for storm damage repairs
NEW AT NOON, THE YORK COUNTY OFFICE OF EMERGENCY MANAGEMENT SAYS THE COUNTY DID NOT QUALIFY TO RECEIVE LOW INTEREST LOANS FROM THE US. SMALL BUSINESS ...
August 25, 2023, 9:59 pm
Neurocrine needs a meaningful clinical win to break out, and crinecerfont could do it
Neurocrine Biosciences needs a clinical win after years of disappointing results and stagnant stock performance. The upcoming Phase III data on crinec...
August 25, 2023, 6:01 pm
Evelo biosciences: may be worth a small, highly speculative long position considering upcoming psoriasis phase 2 results
Following recent cash raise, EVLO has enough (barely) cash to the next catalyst, phase 2 readout in psoriasis. The event is binary and can make or bre...
August 25, 2023, 5:08 pm
Amd is not worth buying
AMD's data center revenue fell 11% in Q2 2023, while Nvidia's data center revenue grew by 171%. AMD fail...
August 25, 2023, 3:55 pm